Quantification of Cell-free DNAfor the Analysis of CD19-CAR-T Cells During Lymphoma Treatment

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2021 Dec 2

PMID 34853800

Citations 8

Authors

Thomas Mika

Julia Thomson

Verena Nilius-Eliliwi

Deepak Vangala

Alexander Baraniskin

Gerald Wulf

Susanne Klein-Scory

Roland Schroers

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR)-T cells are increasingly used for the treatment of hematologic malignancies. Treatment success relies highly upon sufficient expansion of CAR-T effector cells. Accordingly, longitudinal quantification of CAR-T cells during therapy is clinically important. Techniques to quantify CAR-T cells in patient blood samples are based on flow cytometry and PCR. However, cellular kinetics of CAR-T cells are very complex and under current investigation. In this study, feasibility of CAR-T cell quantification by cell-free DNA (cfDNA) was analyzed. cfDNA isolated from 74 blood samples of 12 patients during lymphoma treatment with the anti-CD19 CAR-T cell product axicabtagene ciloleucel (axi-cel) were analyzed. Concentrations of cfDNA specific for the CAR-T gene construct (cfCAR-DNA) and a reference gene were quantified by a newly designed digital-droplet PCR (ddPCR) assay. Detection and quantification of cfCAR-DNA was feasible and reliable for all patients included. Relative quantification of cfCAR-DNA compared to a reference gene, suitable for genomic DNA analysis, was heterogeneous in treatment responders and non-responders. In contrast, parallel analyses of cfCAR-DNA and reference cfDNA in a patient-specific approach gave insight into active lymphoma killing and treatment responses. In summary, plasma cfDNA determination in lymphoma patients is a promising tool for future clinical decision making.

Citing Articles

Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention.

Li J, Chen H, Xu C, Hu M, Li J, Chang W Front Immunol. 2024; 15:1422591.

PMID: 39253080 PMC: 11381299. DOI: 10.3389/fimmu.2024.1422591.

Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.

Olejarz W, Sadowski K, Szulczyk D, Basak G Int J Mol Sci. 2024; 25(14).

PMID: 39062986 PMC: 11276786. DOI: 10.3390/ijms25147743.

Editorial: Liquid biopsies in hematological malignancies.

Garcia-Silva S, Marchetti D, Gallardo M Front Immunol. 2024; 15:1440394.

PMID: 38933278 PMC: 11199863. DOI: 10.3389/fimmu.2024.1440394.

Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment.

Yao S, Han Y, Yang M, Jin K, Lan H Front Immunol. 2023; 14:1292861.

PMID: 38077354 PMC: 10702507. DOI: 10.3389/fimmu.2023.1292861.

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL.

Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L Blood Adv. 2023; 7(22):6844-6849.

PMID: 37748131 PMC: 10679803. DOI: 10.1182/bloodadvances.2023010364.

References

Saukkonen K, Lakkisto P, Pettila V, Varpula M, Karlsson S, Ruokonen E . Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin Chem. 2008; 54(6):1000-7. DOI: 10.1373/clinchem.2007.101030. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Mika T, Baraniskin A, Ladigan S, Wulf G, Dierks S, Haase D . Digital droplet PCR-based chimerism analysis for monitoring of hematopoietic engraftment after allogeneic stem cell transplantation. Int J Lab Hematol. 2019; 41(5):615-621. DOI: 10.1111/ijlh.13073. View

Badbaran A, Berger C, Riecken K, Kruchen A, Geffken M, Muller I . Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR. Cancers (Basel). 2020; 12(7). PMC: 7409173. DOI: 10.3390/cancers12071970. View

Singh A, Chen W, Zheng X, Mody H, Carpenter T, Zong A . Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T. CPT Pharmacometrics Syst Pharmacol. 2021; 10(4):362-376. PMC: 8099446. DOI: 10.1002/psp4.12598. View

Benmebarek M, Karches C, Cadilha B, Lesch S, Endres S, Kobold S . Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019; 20(6). PMC: 6470706. DOI: 10.3390/ijms20061283. View

Armbruster D, Pry T . Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008; 29 Suppl 1:S49-52. PMC: 2556583. View

Klein-Scory S, Wahner I, Maslova M, Al-Sewaidi Y, Pohl M, Mika T . Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer. Front Oncol. 2020; 10:1115. PMC: 7378792. DOI: 10.3389/fonc.2020.01115. View

Hirayama A, Gauthier J, Hay K, Voutsinas J, Wu Q, Gooley T . The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019; 133(17):1876-1887. PMC: 6484391. DOI: 10.1182/blood-2018-11-887067. View

10.

Simonetta F, Alam I, Lohmeyer J, Sahaf B, Good Z, Chen W . Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. Clin Cancer Res. 2020; 27(4):1058-1068. PMC: 7887027. DOI: 10.1158/1078-0432.CCR-20-2770. View

11.

Pott C, Bruggemann M, Ritgen M, van der Velden V, van Dongen J, Kneba M . MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR. Methods Mol Biol. 2019; 1956:199-228. DOI: 10.1007/978-1-4939-9151-8_9. View

12.

Fehse B, Kustikova O, Bubenheim M, Baum C . Pois(s)on--it's a question of dose. Gene Ther. 2004; 11(11):879-81. DOI: 10.1038/sj.gt.3302270. View

13.

Hattori K, Sakata-Yanagimoto M, Suehara Y, Yokoyama Y, Kato T, Kurita N . Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2017; 109(1):225-230. PMC: 5765295. DOI: 10.1111/cas.13450. View

14.

Mouliere F, Chandrananda D, Piskorz A, Moore E, Morris J, Ahlborn L . Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018; 10(466). PMC: 6483061. DOI: 10.1126/scitranslmed.aat4921. View

15.

Khier S, Lohan L . Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. 2018; 4(4):FSO295. PMC: 5905581. DOI: 10.4155/fsoa-2017-0140. View

16.

Gormally E, Caboux E, Vineis P, Hainaut P . Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007; 635(2-3):105-117. DOI: 10.1016/j.mrrev.2006.11.002. View

17.

Franke G, Maier J, Wildenberger K, Cross M, Giles F, Muller M . Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia. J Mol Diagn. 2019; 22(1):81-89. DOI: 10.1016/j.jmoldx.2019.08.007. View

18.

Fraietta J, Nobles C, Sammons M, Lundh S, Carty S, Reich T . Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018; 558(7709):307-312. PMC: 6320248. DOI: 10.1038/s41586-018-0178-z. View

19.

Mika T, Ladigan-Badura S, Maghnouj A, Mustafa B, Klein-Scory S, Baraniskin A . Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy. Front Oncol. 2020; 10:568056. PMC: 7759611. DOI: 10.3389/fonc.2020.568056. View

20.

Klein-Scory S, Maslova M, Pohl M, Eilert-Micus C, Schroers R, Schmiegel W . Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer. Transl Oncol. 2018; 11(2):213-220. PMC: 5789760. DOI: 10.1016/j.tranon.2017.12.010. View